World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

World Journal of Biological Psychiatry

Volumn 14, Issue 1, 2013, Pages 2-44

  Hasan, Alkomiet ^a   Falkai, Peter ^a   Wobrock, Thomas ^b   Lieberman, Jeffrey ^c,g   Glenthoj, Birte ^d   Gattaz, Wagner F ^e   Thibaut, Florence ^f   Möller, Hans Jürgen ^a,g   Altamura, A Carlo ^g   Andreasen, Nancy ^g   Barnes, Thomas R E ^g   Ceylan, M Emin ^g   Ollivier, Jorge Ciprian ^g   Crow, Timothy ^g   Danaci, Aysen Esen ^g   David, Anthony ^g   Davidson, Michael ^g   Deakin, Bill ^g   Elkis, Helio ^g   Farde, Lars ^g   Gaebel, Wolfgang ^g   Gallhofer, Bernd ^g   Gerlach, Jes ^g   Hirsch, Steven Richard ^g   Hojaij, Carlos Roberto ^g   Hwang, Michael ^g   Hwo, Hai Gwo ^g   Jablensky, Assen Verniaminov ^g   Jarema, Marek ^g   Kane, John ^g   Kojima, Takuja ^g   Larach, Veronica ^g   McGorry, Patrick ^g   Meltzer, Herbert ^g   Mosolov, S ^g   Moussaoui, Driss ^g   Oli, Jean Pierre ^g   Palha, Antonio Pacheco ^g   Sarandöl, Asli ^g   Sato, Mitsumoto ^g   Sauer, Heinrich ^g   Schooler, Nina ^g   Taneli, Bilgen ^g   Knorring, Lars von ^g   Weinberger, Daniel ^g   Yamawaki, Shigeto ^g   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Darmstadt Dieburg Clinics   (Germany)

^c Columbia University ^*  (United States)

^d Mental Health Services CPH   (Denmark)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f HÔPITAL CHARLES NICOLLE   (France)

^g NONE   (Portugal)

Author keywords

Antipsychotics; Evidence based guidelines; Long term treatment; Schizophrenia; Side effects

Indexed keywords

AMANTADINE; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; METFORMIN; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERAZINE; PERPHENAZINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; ROSIGLITAZONE; SERTINDOLE; SIBUTRAMINE; TOPIRAMATE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

AGRANULOCYTOSIS; AKATHISIA; ARTICLE; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; CONSTIPATION; DIABETES MELLITUS; DIET THERAPY; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DYSMENORRHEA; DYSTONIA; EARLY INTERVENTION; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYNDROME; GALACTORRHEA; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; INTERMETHOD COMPARISON; LONG TERM CARE; MENTAL PATIENT; METABOLIC DISORDER; MONOTHERAPY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; OBESITY; PARKINSONISM; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PROLACTIN BLOOD LEVEL; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL WELL BEING; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; QUALITY OF LIFE; SCHIZOPHRENIA; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84872356828     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2012.739708     Document Type: Article

References (321)

1. Abhijnhan A, Adams CE, David A, Ozbilen M. 2007. Depot fl uspirilene for schizophrenia. Cochrane Database Syst Rev CD001718.
2. Adams CE, Fenton MK, Quraishi S, David AS. 2001. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia . Br J Psychiatry 179: 290-299.
3. Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, et al. 2009. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 23: 157-162.
4. Alabed S, Latifeh Y, Mohammad HA, Rifai A. 2011. Gammaaminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000203.
5. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
6. Alper K, Schwartz KA, Kolts RL, Khan A. 2007. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62: 345-354.
7. Alphs L, Bossie CA, Sliwa JK, Ma YW, Turner N. 2011. Onset of effi cacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry 10: 12.
8. Altamura AC, Glick ID. 2010. Designing outcome studies to determine effi cacy and safety of antipsychotics for ' real world ' treatment of schizophrenia. Int J Neuropsychopharmacol 13: 971-973.
9. Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S. 2004. Atypical antipsychotic induced weight gain: pathophysiology and management. Ann Clin Psychiatry 16: 75-85.
10. Anghelescu I, Klawe C, Benkert O. 2000. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 20: 716-717.
11. APA. 1997. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry 154: 1-63.
12. APA. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65: 267-272.
13. Arman S, Sadramely MR, Nadi M, Koleini N. 2008. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 29: 1130-1134.
14. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. 2003. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 18: 457-461.
15. Atmaca M, Kologlu M, Tezcan E, Ustundag B, Kilic N. 2004. Nizatidine for the treatment of patients with quetiapineinduced weight gain. Hum Psychopharmacol 19: 37-40.
16. Awad AG, Voruganti LN. 2004. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18: 877-893.
17. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, et al. 2010. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 71: 103-108.
18. Bai YM, Yu SC, Lin CC. 2003. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebocontrolled study. J Clin Psychiatry 64: 1342-1348.
19. Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. 2005. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol 20: 79-85.
20. Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM, et al. 2006. A comparative effi cacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 39: 135-141.
21. Bai YM, Ting Chen T, Chen JY, Chang WH, Wu B, Hung CH, et al. 2007. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 68: 1218-1225.
22. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, et al. 2008a. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders-fi rst revision. World J Biol Psychiatry 9: 248-312.
23. Bandelow B, Zohar J, Kasper S, Moller HJ. 2008b. How to grade categories of evidence. World J Biol Psychiatry 9: 242-247.
24. Baptista T, Hernandez L, Prieto LA, Boyero EC, de Mendoza S. 2001. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 62: 653-655.
25. Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, et al. 2006. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebocontrolled trial. Can J Psychiatry 51: 192-196.
26. Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcategui E, et al. 2007. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 93: 99-108.
27. Baptista T, Uzcategui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, et al. 2008. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 159: 250-253.
28. Baptista T, Rangel N, El Fakih Y, Uzcategui E, Galeazzi T, Beaulieu S, et al. 2009. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 42: 14-19.
29. Barinas-Mitchell E, Kuller LH, Pietropaolo S, Zhang YJ, Henderson T, Pietropaolo M. 2006. The prevalence of the 65-kilodalton isoform of glutamic acid decarboxylase autoantibodies by glucose tolerance status in elderly patients from the cardiovascular health study. J Clin Endocrinol Metab 91: 2871-2877.
30. Bassitt DP, Louza Neto MR. 1998. Clozapine effi cacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 248: 209-211.
31. Bhoopathi PS, Soares-Weiser K. 2006. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 3: CD000205. Birt J. 2003. Management of weight gain associated with antipsychotics. Ann Clin Psychiatry 15: 49-58.
32. Bliesener N, Yokusoglu H, Quednow BB, Klingmuller D, Kuhn KU. 2004. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report. Pharmacopsychiatry 37: 189-191.
33. Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. 1994. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med 24: 307-316.
34. Borba CP, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC. 2011. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacol 31: 653-658.
35. Bradford DW, Perkins DO, Lieberman JA. 2003. Pharmacological management of fi rst-episode schizophrenia and related nonaffective psychoses. Drugs 63: 2265-2283.
36. Buchanan RW. 1995. Clozapine: effi cacy and safety. Schizophr Bull 21: 579-591.
37. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36: 71-93.
38. Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, et al. 2003. Treatment of weight gain with fl uoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 28: 527-529.
39. Caroff SN, Mann SC. 1988. Neuroleptic malignant syndrome. Psychopharmacol Bull 24: 25-29.
40. Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, et al. 2011. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 72: 295-303.
41. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Breier AF. 1999. Diazepam treatment of early signs of exacerbation in schizophrenia . Am J Psychiatry 156: 299-303.
42. Carriere P, Bonhomme D, Lemperiere T. 2000. Amisulpride has a superior benefi t/risk profi le to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15: 321-329.
43. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, et al. 2003. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berlin) 166: 391-399.
44. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. 2004. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 65: 187-190.
45. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. 2003. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 13: 81-85.
46. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, et al. 2006. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes (London) 30: 1011-1016.
47. Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML. 2008. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 32: 925-931.
48. Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al. 2010. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted fi rst episode psychosis: randomised controlled trial. BMJ 341: c4024.
49. Cheung HK. 1981. Schizophrenics fully remitted on neuroleptics for 3-5 years-to stop or continue drugs? Br J Psychiatry 138: 490-494.
50. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. 2005. Comparative effi cacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15: 111-117.
51. Ciliberto N, Bossie CA, Urioste R, Lasser RA. 2005. Lack of impact of race on the effi cacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 20: 207-212.
52. Citrome L. 2009. Olanzapine pamoate: a stick in time? A review of the effi cacy and safety profi le of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 63: 140-150.
53. Citrome L. 2010. Paliperidone palmitate-review of the effi cacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 64: 216-239.
54. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. 2000. Long-term safety and effi cacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 15: 13-22.
55. Cookson IB. 1987. The effects of a 50% reduction of cis(z)-fl upenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. Int Clin Psychopharmacol 2: 141-149.
56. Correa N, Opler LA, Kay SR, Birmaher B. 1987. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 7: 91-95.
57. Correll CU, Schenk EM. 2008. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21: 151-156.
58. Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, et al. 2008. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 28: 69-73.
59. Cramer JA, Rosenheck R. 1998. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49: 196-201.
60. Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, et al. 2010. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol 20: 829-838.
61. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. 1986. A randomised controlled trial of prophylactic neuroleptic treatment . Br J Psychiatry 148: 120-127.
62. Csernansky JG, Mahmoud R, Brenner R. 2002. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 346: 16-22.
63. David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. 2005. Depot fl uphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev CD000307.
64. Davis JM. 1975. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 132: 1237-1245.
65. Davis JM. 1985. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 46: 18-21.
66. Davis JM, Chen N. 2003. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 64(Suppl 16): 24-33.
67. Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, et al. 1993. Dose response of prophylactic antipsychotics. J Clin Psychiatry 54(Suppl): 24-30.
68. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. 1994. Depot antipsychotic drugs. Place in therapy. Drugs 47: 741-773.
69. Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the effi cacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
70. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. 2006. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2: 14.
71. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. 2008. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in fi rst-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 101: 295-303.
72. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. 2009. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24: 412-424.
73. De Hert M, Hudyana H, Dockx L, Bernagie C, Sweers K, Tack J, et al. 2010. Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry 26: 34-44.
74. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. 2011a. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10: 52-77.
75. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. 2011b. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8: 114-126.
76. Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, et al. 2005. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 15: 13-21.
77. Desilets AR, Dhakal-Karki S, Dunican KC. 2008. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 42: 817-826.
78. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, et al. 2010. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 10: 43.
79. Detke HC, Zhao F, Garhyan P, Carlson J, McDonnell D. 2011. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol 26: 35-42.
80. Devinsky O, Honigfeld G, Patin J. 1991. Clozapine-related seizures. Neurology 41: 369-371.
81. DGPPN. 2006. S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1-Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff-Verlag.
82. Dixon LB, Lehman AF, Levine J. 1995. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 21: 567-577.
83. Dixon LB, Perkins B, Calmes C. 2009. Guideline Watch (September 2009): Practice Guideline for the treatment of patients with scizophrenia.
84. Dupuis B, Catteau J, Dumon JP, Libert C, Petit H. 1987. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 144: 802-805.
85. Dursun SM, Devarajan S. 2000. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 45: 198.
86. El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. 2006. Non-neuroleptic catecholaminergic drugs for neurolepticinduced tardive dyskinesia. Cochrane Database Syst Rev CD000458.
87. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. 2004. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65: 696-701.
88. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. 2008. Remission in patients with fi rst-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 23: 325-331.
89. Essock SM, Hargreaves WA, Covell NH, Goethe J. 1996. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 32: 683-697.
90. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. 2006. Effectiveness of switching antipsychotic medications. Am J Psychiatry 163: 2090-2095.
91. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. 2005. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6: 132-191.
92. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. 2006. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7: 5-40.
93. Farinde A. 2011. The impact of topiramate (Topamax(R)) therapy on the development of aggressive and/or agitated behavior. J Pharm Pract 24: 568-570.
94. Faulkner G, Cohn T, Remington G. 2007a. Interventions to reduce weight gain in schizophrenia. Schizophr Bull 33: 654-656.
95. Faulkner G, Cohn T, Remington G. 2007b. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev C D 005148.
96. Fleischhacker WW, Roth SD, Kane JM. 1990. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 10: 12-21.
97. Fleischhacker WW, Hummer M. 1997. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 53: 915-929.
98. Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, et al. 2011. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol Jul 22: 1-12. [ Epub ahead of print].
99. Floris M, Lejeune J, Deberdt W. 2001. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 11: 181-182.
100. Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M, et al. 2002. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 53: 145-159.
101. Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al. 2007. Maintenance treatment with risperidone or low-dose haloperidol in fi rst-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 68: 1763-1774.
102. Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, et al. 2010. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 35: 2367-2377.
103. Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al. 2011. Relapse prevention in fi rstepisode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 72: 205-218.
104. Ganguli R. 2007. Behavioral therapy for weight loss in patients with schizophrenia. J Clin Psychiatry 68(Suppl 4): 19-25.
105. Ganguli R, Brar JS, Garbut R, Chang CC, Basu R. 2011. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses 5: 75-79.
106. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. 1995. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52: 173-188.
107. Glassman AH, Bigger JT Jr. 2001. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158: 1774-1782.
108. Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, et al. 2011. Mid-term and long-term effi cacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry 72: 1616-1627.
109. Goff DC, Hill M, Freudenreich O. 2010. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder . J Clin Psychiatry 71(Suppl 2): 20-26.
110. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. 2010a. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 26: 377-387.
111. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. 2010b. Effi cacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, doseresponse study. Int Clin Psychopharmacol 25: 247-256.
112. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. 2011. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia . J Psychopharmacol 25: 685-697.
113. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. 2005. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162: 1744-1746.
114. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, et al. 2006. Olanzapine and haloperidol in fi rst episode psychosis: two-year data. Schizophr Res 86: 234-243.
115. Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, et al. 2011. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 134: 187-194.
116. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. 2009. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10: 85-116.
117. Gupta S, Masand PS, Virk S, Schwartz T, Hameed A, Frank BL, et al. 2004. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 70: 57-62.
118. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, et al. 2011. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72: 1222-1228.
119. Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. 1998. Olanzapine versus placebo and haloperidol: quality of life and effi cacy results of the North American double-blind trial. Neuropsychopharmacology 18: 41-49.
120. Hamilton SH, Edgell ET, Revicki DA, Breier A. 2000. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 15: 245-255.
121. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D. 2007. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17: 235-244.
122. Harrison TS, Goa KL. 2004. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 18: 113-132.
123. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. 2012. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13: 318-378.
124. Hay DP, Hay L, Blackwell B, Spiro HR. 1990. ECT and tardive dyskinesia. J Geriatr Psychiatry Neurol 3: 106-109.
125. Heimberg C, Gallacher F, Gurc FC, Gur RE. 1995. Diet and gender moderate clozapine-related weight gain. Hum Psychopharmacol 10: 376-371.
126. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, et al. 2005a. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 162: 954-962.
127. Henderson DC, Louie PM, Koul P, Namey L, Daley TB, Nguyen DD. 2005b. Modafi nil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Ann Clin Psychiatry 17: 95-97.
128. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, et al. 2007. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 115: 101-105.
129. Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, et al. 2009. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand 119: 457-465.
130. Henderson DC, Freudenreich O, Borba CP, Wang X, Copeland PM, Macklin E, et al. 2011. Effects of modafi nil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res 130: 53-56.
131. Hill AL, Sun B, Karagianis JL, Watson SB, McDonnell DP. 2011. Dose-associated changes in safety and effi cacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry 11: 28.
132. Hoffmann VP, Case M, Jacobson JG. 2012. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. J Clin Psychiatry 73: 216-23.
133. Hogarty GE, Ulrich RF. 1998. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 32: 243-250.
134. Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, et al. 1988. Dose of fl uphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Arch Gen Psychiatry 45: 797-805.
135. Holt RI, Peveler RC. 2011. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxford) 74: 141-147.
136. Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, et al. 2009. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33: 1022-1031.
137. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. 2010. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 116: 107-117.
138. Jean-Baptiste M, Tek C, Liskov E, Chakunta UR, Nicholls S, Hassan AQ, et al. 2007. A pilot study of a weight management program with food provision in schizophrenia. Schizophr Res 96: 198-205.
139. Jeste DV, Lacro JP, Gilbert PL, Kline J, Kline N. 1993. Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 19: 817-830.
140. Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, et al. 2008. Orlistat in clozapine-or olanzapinetreated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69: 706-711.
141. Johnson DA. 1976. The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand 53: 298-301.
142. Johnson DA, Ludlow JM, Street K, Taylor RD. 1987. Double-blind comparison of half-dose and standard-dose fl upenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br J Psychiatry 151: 634-638.
143. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. 2006. Randomized controlled trial of the effect on Quality of Life of second-vs fi rst-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079-1087.
144. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. 2008. Effectiveness of antipsychotic drugs in fi rst-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085-1097.
145. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. 1982. Fluphenazine vs placebo in patients with remitted, acute fi rstepisode schizophrenia. Arch Gen Psychiatry 39: 70-73.
146. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, et al. 1983. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 40: 893-896.
147. Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, et al. 2002. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 159: 554-560.
148. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. 2003. Long-acting injectable risperidone: effi cacy and safety of the fi rst long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132.
149. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, et al. 2010. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 167: 181-189.
150. Kaneda Y, Kawamura I, Fujii A, Ohmori T. 2004. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia . Neuro Endocrinol Lett 25: 135-140.
151. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. 2003. Effi cacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6: 325-337.
152. Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M. 2006. Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res 81: 139-143.
153. Keks NA, Ingham M, Khan A, Karcher K. 2007. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 191: 131-139.
154. Kilian R, Steinert T, Schepp W, Weiser P, Jaeger S, Pfi ffner C, et al. 2012. Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. Eur Arch Psychiatry Clin Neurosci 262: 589-598.
155. Kim JH, Yim SJ, Nam JH. 2006. A 12-week, randomized, openlabel, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 82: 115-117.
156. Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, et al. 2002. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 63: 408-413.
157. Kimiagar I, Dobronevsky E, Prokhorov T, Miniovitz A, Rabey JM. 2011. Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study. J Neurol 259: 660-664.
158. Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. 2004. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 28: 985-996.
159. Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. 2006. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31: 577-588.
160. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. 2011. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus fi rst-generation antipsychotics. Mol Psychiatry, 18: 53-66.
161. Kissling W. 1991. Guidelines for neuroleptic relapse prevention in schizophrenia. Kissling W, ed. Berlin: Springer.
162. Kissling W, Glue P, Medori R, Simpson S. 2007. Long-term safety and effi cacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol 22: 505-513.
163. Ko YH, Joe SH, Jung IK, Kim SH. 2005. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 28: 169-175.
164. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, et al. 2010. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled effi cacy and safety study. Int J Neuropsychopharmacol 13: 635-647.
165. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. 2010. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 36: 94-103.
166. Kumar R, Sachdev PS. 2009. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 22: 293-299.
167. Kutcher S, Williamson P, MacKenzie S, Marton P, Ehrlich M. 1989. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a doubleblind, placebo-controlled study. J Clin Psychopharmacol 9: 403-406.
168. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, et al. 2006. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 67: 1690-1697.
169. Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. 2005. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 72: 249-258.
170. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. 2008. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 69: 790-799.
171. Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. 2009. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 66: 713-720.
172. Lee BH, Kim YK, Park SH. 2006. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 30: 714-717.
173. Lee MS, Song HC, An H, Yang J, Ko YH, Jung IK, et al. 2010. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci 64: 19-27.
174. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161: 1-56.
175. Lerner V, Bergman J, Statsenko N, Miodownik C. 2004. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 65: 1550-1554.
176. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. 2003. Relapse prevention in schizophrenia with newgeneration antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160: 1209-1222.
177. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. 2009a. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14: 429-447.
178. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. 2009b. Second-generation versus fi rst-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41.
179. Leucht S, Kissling W, Davis JM. 2009c. How to read and understand and use systematic reviews and meta-analyses. Acta Psychiatr Scand 119: 443-450.
180. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. 2011a. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127: 83-92.
181. Leucht S, Heres S, Kissling W, Davis JM. 2011b. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 14: 269-284.
182. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. 2012a. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 5: CD008016.
183. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. 2012b. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and metaanalysis . Lancet 379: 2063-2071.
184. Leung JG, Breden EL. 2011. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 45: 525-531.
185. Li H, Rui Q, Ning X, Xu H, Gu N. 2011. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35: 1002-1008.
186. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. 1991. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158: 503-510.
187. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. 2003. Atypical and conventional antipsychotic drugs in treatment-naive fi rst-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28: 995-1003.
188. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353: 1209-1223.
189. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. 2002. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev C D 001950.
190. Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K. 2004a. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev CD001946.
191. Lima AR, Weiser KV, Bacaltchuk J, Barnes TR. 2004b. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev CD003727.
192. Lindenmayer JP, Khan A. 2011. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res 125: 267-277.
193. Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S. 2007. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 17: 138-144.
194. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. 2003. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 35: 237-241.
195. Lopez-Mato A, Rovner J, Illa G, Vieitez A, Boullosa O. 2003. [Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration]. Vertex 14: 85-96.
196. Louza MR, Bassitt DP. 2005. Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years ' follow-up. J Clin Psychopharmacol 25: 180-182.
197. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. 2004. Adjunctive fl uvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65: 766-771.
198. Lu ML, Shen WW, Chen CH. 2008. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 32: 1978-1981.
199. Lyons MK. 2011. Deep brain stimulation: current and future clinical applications. Mayo Clin Proc 86: 662-72.
200. Mahmoud R, Engelhart L, Ollendorf D, Oster G. 1999. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry 60(Suppl 3): 42-47; discussion 48.
201. Manu P, Sarpal D, Muir O, Kane JM, Correll CU. 2011. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 134: 180-186.
202. Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, et al. 1984. Costs and benefi ts of two doses of fl uphenazine. Arch Gen Psychiatry 41: 1025-1029.
203. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, et al. 2003. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 160: 1405-1412.
204. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. 2004. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349.
205. Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G. 1986. Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Jpn J Psychiatry Neurol 40: 639-646.
206. Mauri M, Castrogiovanni S, Simoncini M, Iovieno N, Miniati M, Rossi A, et al. 2006. Effects of an educational intervention on weight gain in patients treated with antipsychotics. J Clin Psychopharmacol 26: 462-466.
207. McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, et al. 2010. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 10: 45.
208. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. 2007. Effi cacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1050-1060.
209. Melamed E, Achiron A, Shapira A, Davidovicz S. 1991. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuropharmacol 14: 273-278.
210. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. 2003. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60: 82-91.
211. Mendhekar DN, Jiloha RC, Mehndiratta MM, War L. 2002. Challenge with atypical antipsychotic drugs in risperidone induced neuroleptic malignant syndrome: a case report. Indian J Psychiatry 44: 387-390.
212. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. 2004. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 65: 471-477.
213. Miller DD. 2000. Review and management of clozapine side effects. J Clin Psychiatry 61(Suppl 8): 14-17; discussion 18-19.
214. Miller DE, Sebastian CS. 2005. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. J Clin Psychiatry 66: 269-270.
215. Miodownik C, Lerner V, Statsenko N, Dwolatzky T, Nemets B, Berzak E, et al. 2006. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, doubleblind, controlled study. Clin Neuropharmacol 29: 68-72.
216. Moller HJ. 2004. Novel antipsychotics in the long-term treatment of schizophrenia. World J Biol Psychiatry 5: 9-19.
217. Moller HJ. 2008. Do effectiveness ("real world") studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci 258: 257-270.
218. Möller HJ, van Zerssen D. 1995. Course and outcome of schizophrenia . In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford: Blackwell.
219. Montgomery SA, van Zwieten-Boot B. 2007. ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004. Eur Neuropsychopharmacol 17: 70-77.
220. Mukundan A, Faulkner G, Cohn T, Remington G. 2010. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev CD006629.
221. Muscatello MR, Bruno A, Pandolfo G, Mico U, Bellinghieri PM, Scimeca G, et al. 2011. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol 25: 667-674.
222. Naber D, Lambert M. 2009. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 23: 649-659.
223. Narula PK, Rehan HS, Unni KE, Gupta N. 2010. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 118: 218-223.
224. Nasrallah HA. 2007. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115: 260-267.
225. Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, et al. 2010. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 35: 2072-2082.
226. Newcomer JW. 2007. Metabolic syndrome and mental illness. Am J Manag Care 13: S170-177.
227. Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, et al. 2008. A multicenter, randomized, doubleblind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 69: 1046-1056.
228. NICE. 2002. National Institute of Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guideance No. 54. www.nice.org.ik.
229. NICE. 2010. The NICE Guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). London: The British Psychological Society.
230. Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. 2011. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 25: 473-490.
231. Norgard NB, Stark JE. 2006. Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 26: 1180-1182.
232. Odejide OA, Aderounmu AF. 1982. Double-blind placebo substitution: withdrawal of fl uphenazine decanoate in schizophrenic patients. J Clin Psychiatry 43: 195-196.
233. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. 2009. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24: 287-296.
234. Pacia SV, Devinsky O. 1994. Clozapine-related seizures: experience with 5,629 patients. Neurology 44: 2247-2249.
235. Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, et al. 2010. A randomized, placebo-controlled study to assess the effi cacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 30: 235-244.
236. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. 2011. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35: 218-226.
237. Patel MX, Taylor M, David AS. 2009. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl 52: S1-4.
238. Pope HG Jr, Aizley HG, Keck PE Jr, McElroy SL. 1991. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. J Clin Psychiatry 52: 208-212.
239. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, et al. 2006. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 85: 254-265.
240. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, et al. 2002. Olanzapine-induced weight gain in patients with fi rst-episode schizophrenia: a double-blind, placebo-controlled study of fl uoxetine addition. Am J Psychiatry 159: 1058-1060.
241. Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. 2004. The effect of famotidine addition on olanzapine-induced weight gain in fi rst-episode schizophrenia patients: a doubleblind placebo-controlled pilot study. Eur Neuropsychopharmacol 14: 332-336.
242. Praharaj SK, Jana AK, Goyal N, Sinha VK. 2011. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol 71: 377-382.
243. Pujalte D, Bottai T, Hue B, Alric R, Pouget R, Blayac JP, et al. 1994. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol 17: 236-242.
244. Purgato M, Adams CE. 2011. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev 9: CD001719.
245. Quaraishi SN, David A, Brasil MA, Alheriar FV. 1999 Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev 2004; (3) : CD001719.
246. Rabinowitz J, Hornik T, Davidson M. 2001. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry 62: 343-346.
247. RANZCP. 2005. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry 39: 1-30.
248. Rathbone J, Soares-Weiser K. 2011. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev C D 003727.
249. Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, et al. 2008. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res 35: 215-225.
250. Reulbach U, Dutsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J, et al. 2007. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 11: R4.
251. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. 1999. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 8: 417-426.
252. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. 1999. Predictors of relapse following response from a fi rst episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241-247.
253. Roden DM. 2004. Drug-induced prolongation of the QT interval . New Engl J Med 350: 1013-1022.
254. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. 1997. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New Engl J Med 337: 809-815.
255. Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, et al. 1998. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia . Health Serv Res 33: 1237-1261.
256. Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, et al. 1999. Impact of clozapine on negative symptoms and on the defi cit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Am J Psychiatry 156: 88-93.
257. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. 2003. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. J Am Med Assoc 290: 2693-2702.
258. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, et al. 2006. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 163: 2080-2089.
259. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al. 2009. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 107: 22-29.
260. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. 2011. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New Engl J Med 364: 842-851.
261. Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. 2006. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51: 531-539.
262. Sacchetti E, Guarneri L, Bravi D. 2000. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 48: 167-168.
263. Sakkas P, Davis JM, Janicak PG, Wang ZY. 1991. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 27: 381-384.
264. Sako W, Goto S, Shimazu H, Murase N, Matsuzaki K, Tamura T, et al. 2008. Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia. Mov Disord 23: 1929-1931.
265. Saleem P, Olie JP, Loo H. 2002. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. Int Clin Psychopharmacol 17: 1-8.
266. Sampath G, Sha A, Krska J, Soni S. 1992. Neuroleptic discontinuation in the very stable schizophrenic patient-relapse rates and serum neurolepti levels. Human Psychopharmacol Clin Exp 7: 255-264.
267. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. 2005. Risperidone and haloperidol in fi rst-episode psychosis: a long-term randomized trial. Am J Psychiatry 162: 947-953.
268. Schooler NR. 1993. Reducing dosage in maintenance treatment of schizophrenia. Review and prognosis. Br J Psychiatry Suppl 22: 58-65.
269. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, et al. 1997. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 54: 453-463.
270. Semple D, Smyth R. 2009. Oxford Handbook of Psychiatry. Oxford: Oxford University Press.
271. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. 2007. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 164: 1404-1410.
272. Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. 2006. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 67: 1194-1203.
273. Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E. 1990. Acute dystonia during fi xed-dose neuroleptic treatment. J Clin Psychopharmacol 10: 389-396.
274. Sliwa JK, Bossie CA, Ma YW, Alphs L. 2011. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res 132: 28-34.
275. Soares-Weiser KV, Joy C. 2003. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000208.
276. Soares KV, McGrath JJ. 2000. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000204.
277. Soares-Weiser K, Rathbone J. 2004. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000206.
278. Soares-Weiser K, Rathbone J. 2006. Neuroleptic reduction and/or cessation and neuroleptics as specifi c treatments for tardive dyskinesia. Cochrane Database Syst Rev CD000459.
279. Soares-Weiser K, Maayan N, McGrath J. 2011. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000209.
280. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, et al. 1997. Clozapine treatment for neurolepticinduced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 58: 318-322.
281. Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, et al. 2005. Quality of life during treatment with haloperidol or olanzapine in the year following a fi rst psychotic episode. Schizophr Res 78: 161-169.
282. Strawn JR, Keck PE Jr, Caroff SN. 2007. Neuroleptic malignant syndrome. Am J Psychiatry 164: 870-876.
283. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611-622.
284. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. 2007. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164: 415-427.
285. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, et al. 2009. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107: 1-12.
286. Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al. 2011. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168: 947-956.
287. Stryjer R, Rosenzcwaig S, Bar F, Ulman AM, Weizman A, Spivak B. 2010. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol 33: 219-222.
288. Sumic JC, Baric V, Bilic P, Herceg M, Sisek-Sprem M, Jukic V. 2007. QTc and psychopharmacs: are there any differences between monotherapy and polytherapy. Ann Gen Psychiatry 6: 13.
289. Supprian T. 2004. Therapie. In: Assion HJ, Volz HP, eds. Malgnes neuroleptisches Syndrom. Stuttgart, New York: Thieme. p. 28-34.
290. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al. 2007. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: fi ndings from the NIMH CATIE study. Am J Psychiatry 164: 428-436.
291. Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. 2012. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 134: 219-225.
292. Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. 2002. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev CD000207.
293. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. 1994. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 55(Suppl B): 102-106.
294. Tchoukhine E, Takala P, Hakko H, Raidma M, Putkonen H, Rasanen P, et al. 2011. Orlistat in clozapine-or olanzapinetreated patients with overweight or obesity: a 16-week openlabel extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 72: 326-330.
295. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J. 2005. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 66: 1130-1133.
296. Tenback DE, van Harten PN, Slooff CJ, van Os J. 2010. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol 24: 1031-1035.
297. Thobois S, Poisson A, Damier P. 2011. Surgery for tardive dyskinesia. Int Rev Neurobiol 98: 289-296.
298. Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvarinen S, Eronen M, et al. 2005. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 66: 1012-1015.
299. Trollor JN, Sachdev PS. 1999. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust NZ J Psychiatry 33: 650-659.
300. Trottenberg T, Volkmann J, Deuschl G, Kuhn AA, Schneider GH, Muller J, et al. 2005. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 64: 344-346.
301. Ucok A, Ucok G. 1996. Maintenance ECT in a patient with catatonic schizophrenia and tardive dyskinesia. Convuls Ther 12: 108-112.
302. Umbricht D, Flury H, Bridler R. 2001. Cognitive behavior therapy for weight gain. Am J Psychiatry 158: 971.
303. Venkatasubramanian G, Arasappa R, Rao NP, Behere RV, Gangadhar BN. 2010. Adjuvant metformin worsens psychosis in schizophrenia: a case report. Prim Care Companion J Clin Psychiatry. 12(2). pii: PCC.09l00801.
304. Vinson DR, Drotts DL. 2001. Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. Ann Emerg Med 37: 125-131.
305. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. 2000. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profi le and impact on quality of life. Schizophr Res 43: 135-145.
306. Walburn J, Gray R, Gournay K, Quraishi S, David AS. 2001. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179: 300-307.
307. Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, et al. 2010. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry 167: 676-685.
308. Wang Y, Turnbull I, Calne S, Stoessl AJ, Calne DB. 1997. Pallidotomy for tardive dyskinesia. Lancet 349: 777-778.
309. Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W, Schimmelmann BG, et al. 2008. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. J Psychiatr Res 42: 676-683.
310. Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. 1987. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 144: 1148-1153.
311. Weiden PJ, Daniel DG, Simpson G, Romano SJ. 2003a. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23: 595-600.
312. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. 2003b. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 64: 580-588.
313. Weiden PJ, Kozma C, Grogg A, Locklear J. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55: 886-891.
314. Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. 2008. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33: 985-994.
315. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfi nger SM. 2009. A randomized controlled trial of longacting injectable risperidone vs continuation on oral atypical antipsychotics for fi rst-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 70: 1397-1406.
316. Wells AJ, Sommi RW, Crismon ML. 1988. Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm 22: 475-480.
317. Werneke U, Taylor D, Sanders TA, Wessely S. 2003. Behavioural management of antipsychotic-induced weight gain: a review. Acta Psychiatr Scand 108: 252-259.
318. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. 2002. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63: 856-865.
319. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. 2008. Metformin addition attenuates olanzapine-induced weight gain in drug-naive fi rst-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 165: 352-358.
320. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. 2007. Guided discontinuation versus maintenance treatment in remitted fi rst-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 68: 654-661.
321. Yuan HN, Wang CY, Sze CW, Tong Y, Tan QR, Feng XJ, et al. 2008. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol 28: 264-370.